Photodynamic Therapy as a New Prospective Method for Cancer TreatmentII. Overview of Photosensitizers

Czech version

Authors: P. Zimčík; M. Miletín
Authors‘ workplace: Katedra farmaceutické chemie a kontroly léčiv Farmaceutické fakulty Univerzity Karlovy, Hradec Králové
Published in: Čes. slov. Farm., 2004; , 271-279
Category:

Overview

Since the time when hematoporphyrine derivative (trade name Photofrin®) has been introduced intoclinical practice in Canada in 1993, a lot of new photosensitizers (PS) have been studied. Some ofthem successfully passed the clinical trials and are in use in the treatment of cancerous (ALA,temoporfin) and non-cancerous (verteporfin) diseases. The others (motexafin lutecium, talaporfin,phthalocyanines and SnET2) are entering or passing the clinical trials now. The newer PS are alsocalled the second generation PS,when the first generation is composed of Photofrin® only.The secondgeneration PS usually possesses better properties, especially concerning absorption at longerwavelengths, shorter skin photosensitivity, better accumulation ratio between tumorous and healthytissue and pharmacokinetics.

Key words:
photodynamic therapy – photosensitizer – Photofrin

Full text is not available online.

If interested in a scan of this journal, contact NTO ČLS JEP.